Skip to main content
CVE:SCYB

Scythian Biosciences Competitors

C$3.49
-0.22 (-5.93 %)
(As of 07/25/2018)
Add
Compare
Today's Range
C$3.46
C$3.77
50-Day Range
C$3.49
C$3.49
52-Week Range
C$1.01
C$8.61
Volume703,164 shs
Average Volume231,491 shs
Market CapitalizationC$102.38 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Scythian Biosciences (CVE:SCYB) Vs. CHV, PREV, COM, MYM, CURE, and HALO

Should you be buying SCYB stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Scythian Biosciences, including (CHV) (CHV), (PREV) (PREV), 138267 (COM.TO) (COM), 17031 (MYM), Direxion Daily Healthcare Bull 3X Shares (CURE), and Halozyme Therapeutics (HALO).

(CHV) (CNSX:CHV) and Scythian Biosciences (CVE:SCYB) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings for (CHV) and Scythian Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(CHV)0000N/A
Scythian Biosciences0000N/A

Profitability

This table compares (CHV) and Scythian Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(CHV)N/AN/AN/A
Scythian BiosciencesN/AN/AN/A

Earnings and Valuation

This table compares (CHV) and Scythian Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(CHV)N/AN/AN/AN/AN/A
Scythian BiosciencesN/AN/AN/AN/AN/A

(PREV) (CNSX:PREV) and Scythian Biosciences (CVE:SCYB) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings for (PREV) and Scythian Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(PREV)0000N/A
Scythian Biosciences0000N/A

Profitability

This table compares (PREV) and Scythian Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(PREV)N/AN/AN/A
Scythian BiosciencesN/AN/AN/A

Earnings and Valuation

This table compares (PREV) and Scythian Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(PREV)N/AN/AN/AN/AN/A
Scythian BiosciencesN/AN/AN/AN/AN/A

138267 (COM.TO) (TSE:COM) and Scythian Biosciences (CVE:SCYB) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings for 138267 (COM.TO) and Scythian Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
138267 (COM.TO)0000N/A
Scythian Biosciences0000N/A

Profitability

This table compares 138267 (COM.TO) and Scythian Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
138267 (COM.TO)N/AN/AN/A
Scythian BiosciencesN/AN/AN/A

Earnings and Valuation

This table compares 138267 (COM.TO) and Scythian Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
138267 (COM.TO)N/AN/AN/AN/AN/A
Scythian BiosciencesN/AN/AN/AN/AN/A

17031 (CNSX:MYM) and Scythian Biosciences (CVE:SCYB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for 17031 and Scythian Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
170310000N/A
Scythian Biosciences0000N/A

Profitability

This table compares 17031 and Scythian Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
17031N/AN/AN/A
Scythian BiosciencesN/AN/AN/A

Earnings & Valuation

This table compares 17031 and Scythian Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
17031N/AN/AN/AN/AN/A
Scythian BiosciencesN/AN/AN/AN/AN/A

Direxion Daily Healthcare Bull 3X Shares (CNSX:CURE) and Scythian Biosciences (CVE:SCYB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Direxion Daily Healthcare Bull 3X Shares and Scythian Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Direxion Daily Healthcare Bull 3X Shares0000N/A
Scythian Biosciences0000N/A

Profitability

This table compares Direxion Daily Healthcare Bull 3X Shares and Scythian Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Direxion Daily Healthcare Bull 3X SharesN/AN/AN/A
Scythian BiosciencesN/AN/AN/A

Earnings & Valuation

This table compares Direxion Daily Healthcare Bull 3X Shares and Scythian Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Direxion Daily Healthcare Bull 3X SharesN/AN/AN/AN/AN/A
Scythian BiosciencesN/AN/AN/AN/AN/A

Halozyme Therapeutics (NEO:HALO) and Scythian Biosciences (CVE:SCYB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Halozyme Therapeutics and Scythian Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Halozyme Therapeutics00014.00
Scythian Biosciences0000N/A

Halozyme Therapeutics currently has a consensus target price of C$0.24, suggesting a potential upside of ∞. Given Halozyme Therapeutics' higher probable upside, research analysts plainly believe Halozyme Therapeutics is more favorable than Scythian Biosciences.

Profitability

This table compares Halozyme Therapeutics and Scythian Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Halozyme TherapeuticsN/AN/AN/A
Scythian BiosciencesN/AN/AN/A

Earnings & Valuation

This table compares Halozyme Therapeutics and Scythian Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme TherapeuticsC$267.59 million0.00C$129.57 millionC$0.91N/A
Scythian BiosciencesN/AN/AN/AN/AN/A

Halozyme Therapeutics has higher revenue and earnings than Scythian Biosciences.

Summary

Halozyme Therapeutics beats Scythian Biosciences on 3 of the 3 factors compared between the two stocks.


Scythian Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
HALO
Halozyme Therapeutics
1.3N/AN/AC$0.00C$267.59 million47.29
LTY
Liberty Biopharma
0.6$2.00-100.0%C$0.00N/A-12.66Gap Up
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32-5.3%C$0.00N/A0.00Gap Up
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.